SLC5A2 and hydrops fetalis: Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of heart failure (HF) hospitalizations in patients with T2DM and chronic stable cardiovascular disease as well as in patients with chronic kidney disease, and patients with HF across the range of ejection fraction, in patients with and without T2DM.3